Dissolution of paracetamol suppositories using the flow-through cell system and their absorption in an animal model;Disolución de supositorios de paracetamol utilizando el sistema de celda de flujo continuo y su absorción en un modelo animal

Revista Mexicana de Ciencias Farmaceuticas

Volumn 40, Issue 2, 2009, Pages 11-18

  Medina López, José Raúl ^a   Hurtado Y De La P , Marcela ^a   Cortés A , Alma Rosa ^a   Aoki M , Kazuko ^a   Domínguez R , Adriana Miriam ^a  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

Flow through cell; In vitro in vivo correlation; Paracetamol; Suppositories

Indexed keywords

PARACETAMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RABBIT; SUPPOSITORY;

EID: 68249152009     PISSN: 10273956     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Watts P.J., Illum L. 1997. Colonic drug delivery. Drug Development and Industrial Pharmacy, 23(9):893-913.
2. Coulthard K.P., Nielson H.W., Schroder M., Covino A., Matthews N.T., Murray R.S., Van der Walt J.H. 1998. Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. Journal of Paediatrics and Child Health, 34(5):425-431. (Pubitemid 28481726)
3. Eandi M., Viano I., Ricci Gamalero S. 1984. Absolute bioavailability of paracetamol after oral or rectal administration in healthy volunteers. Arzneimittel-Forschung/Drug Research, 34(II):903-907. (Pubitemid 14099918)
4. FDA, Center for Drug Evaluation and Research. Guidance for Industry-Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. August 2000.
5. Kalantzi L., Reppas C., Dressman J.B., Amidon G.L., Junginger H.E., Midha K.K., Shah V.P., Stavchansky S.A., Barends, D.M. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (Paracetamol). Journal of Pharmaceutical Sciences, 95(1):4-14.
6. Langmaack H.J. 1980. In vitro release of active substances from suppositories. Krankenhaus-Apotheke, 30:91-95.
7. Pulišić M., Usmiani I., Becírević M. 1988. Influence of excipients on the release of paracetamol from suppositories. Farmaceutski Glasnik, 44:287-290.
8. Palmieri A. 1982. Dissolution of suppositories and acetaminophen release. Pharmaceutical Technology, 6:70-80.
9. Palmieri A., Danson T., Groben W., Jukka R., Dummer C. 1983. Dissolution of suppositories part 3. Effect of insoluble polyvinylpyrrolidone on acetaminophen release. Drug Development and Industrial Pharmacy, 9(3):421-442.
10. Gjellan K., Graffner C. 1994. Influence of amount of hard fat in suppositories on the in vitro release rate and bioavailability of paracetamol II. A comparison between three compositions and a rectal solution. International Journal of Pharmaceutics, 104(3):215-226. (Pubitemid 24082472)
11. Hurtado M., Medina J.R., Cortés A.R., Domínguez, A.M. 2002. Perfiles de disolución de supositorios de paracetamol en el aparato 4 USP. Revista Mexicana de Ciencias Farmacéuticas, 33(1):31-35.
12. Janicki S., Sznitowska M., Zebrowska W., Gabiga H., Kupiec M. 2001. Evaluation of paracetamol by pharmacopoeial dissolution test - comments on methodology. European Journal of Pharmaceutics and Biopharmaceutics, 52(2):249-254. (Pubitemid 32755905)
13. Lauroba J., Diez I., Rius M., Peraire C., Doménech J. 1990. Study of the release process of drugs: suppositories of paracetamol. International Journal of Clinical Pharmacology, Therapy and Toxicology, 28(3):118-122. (Pubitemid 20216826)
14. Gjellan K., Graffner C. 1989. Comparative dissolution studies of rectal formulations using the basket, the paddle and the flow-through methods. I. Paracetamol in suppositories and soft gelatin capsules of both hydrophilic and lipophilic types. Acta Pharmaceutica Nordica, 1(6):343-354. (Pubitemid 20083373)
15. USP 28/NF 23. 2005: United States Pharmacopeia. The National Formulary. U.S. Pharmacopeial Convention, Inc., Rockville, MD. p. 18.
16. Farmacopea de los Estados Unidos Mexicanos. 2004. 8a ed. Vol.II. Secretaría de Salud. México. pp. 1955,1956.
17. FDA, Center for Drug Evaluation and Research. Guidance for Industry-Dissolution testing of immediate release solid oral dosage forms. August 1997.
18. Norma Oficial Mexicana NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. Publicada 9 de agosto de 2001. Diario Oficial de la Federación.
19. Frings C.S., Saloom J.M. 1979. Colorimetric method for the quantitative determination of acetaminophen in serum. Clinical Toxicology, 15(1):67-73. (Pubitemid 10250707)
20. Van Bocxlaer J.F., Clauwaert K.M., Lambert W.E., De Leenheer A.P. 1997. Quantitative colorimetric determination of urinary p-aminophenol with an automated analyzer. Clinical Chemistry, 43(4):627-634.
21. Ritschel W.A., Kearns G.L. 1999. Handbook of basic pharmacokinetics including clinical applications. 5a ed. American Pharmaceutical Association, Washington D.C., pp. 242-254.
22. Khan K. 1975. The concept of dissolution efficiency. Journal of Pharmacy and Pharmacology, 27:48-49.
23. Moore J.W., Flanner H.H. 1996. Mathematical comparison of dissolution profiles. Pharmaceutial Technology, 20:64-74.